GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (WBO:MRNA) » Definitions » 5-Year Sharpe Ratio

Moderna (WBO:MRNA) 5-Year Sharpe Ratio : N/A (As of Jul. 16, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Moderna 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2025-07-16), Moderna's 5-Year Sharpe Ratio is Not available.


Competitive Comparison of Moderna's 5-Year Sharpe Ratio

For the Biotechnology subindustry, Moderna's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's 5-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Moderna's 5-Year Sharpe Ratio falls into.


;
;

Moderna 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.


Moderna  (WBO:MRNA) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Moderna 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Moderna's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Address
325 Binney Street, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.